Christina Theodore-Oklota

  • Citations Per Year
Learn More
PURPOSE As glioblastoma progresses, patients experience a decline in health-related quality of life (HRQoL). Delaying this decline is an important treatment goal. In newly diagnosed glioblastoma, progression-free survival was prolonged when bevacizumab was added to radiotherapy plus temozolomide (RT/TMZ) versus placebo plus RT/TMZ (phase III AVAglio study;(More)
Patients with primary brain tumors such as malignant gliomas are highly symptomatic, often from the time of diagnosis. Signs and symptoms (signs/symptoms) can cause functional limitations that often worsen over the disease trajectory and may impact patient quality of life. It is recognized that standard measurements of tumor response do not adequately(More)
Recent research has highlighted the role of hyperresponsivity and numbing of emotions in posttraumatic stress disorder. Preliminary research suggests that emotional numbing symptoms impact the development, maintenance, and treatment of posttraumatic stress disorder. However, research in this area has been hindered, in part, due to the absence of a(More)
This study explored whether adolescents with elevated symptoms of mania (ESM+) engage in more HIV risk behaviors than those with other psychiatric disorders and examined factors associated with HIV risk behavior among ESM+ adolescents. Eight hundred forty adolescents (56% female, 58% African American, M age = 14.9 years) who received mental health treatment(More)
Psychosocial consequences of relational aggression have garnered significant attention. Although most adolescents are targets of relational aggression at some point, only a sub-group experience significant psychological distress and impaired functioning, with research linking experiential avoidance to negative outcomes. The present study sought to develop(More)
Objectives: Instanyl® (fentanyl nasal spray) received European market authorisation in July 2009 for the management of breakthrough pain in adults already receiving maintenance opioid therapy for chronic cancer pain, with precise instructions on indications for use and dosage. The study objectives were to evaluate patientreported misuse, abuse, and(More)
BACKGROUND A subcutaneous (SC) formulation of rituximab (MabThera®/Rituxan®) has been developed that could reduce administration time and improve patient satisfaction with treatment. The Rituximab Administration Satisfaction Questionnaire (RASQ) was created to assess patients' perceptions and satisfaction with rituximab SC (RASQ-SC) or rituximab intravenous(More)
  • 1